Johnson PJ - Search Results

1

Quantitative evaluation of thallium-201 uptake in predicting chemotherapeutic response of osteosarcoma.

Lin J, Leung WT, Ho SK, Ho KC, Kumta SM, Metreweli C, Johnson PJ. Lin J, et al. Among authors: johnson pj. Eur J Nucl Med. 1995 Jun;22(6):553-5. doi: 10.1007/BF00817281. Eur J Nucl Med. 1995. PMID: 7556302

2

Arteriovenous shunts in patients with hepatic tumors.

Ho S, Lau WY, Leung WT, Chan M, Chan KW, Johnson PJ, Li AK. Ho S, et al. Among authors: johnson pj. J Nucl Med. 1997 Aug;38(8):1201-5. J Nucl Med. 1997. PMID: 9255149 Free article.

3

Cerebrovascular event following taxol infusion.

Chan AT, Leung WT, Johnson PJ. Chan AT, et al. Among authors: johnson pj. Clin Oncol (R Coll Radiol). 1994;6(3):202-3. doi: 10.1016/s0936-6555(94)80062-6. Clin Oncol (R Coll Radiol). 1994. PMID: 7916203

4

Determination of tumour vascularity using selective hepatic angiography as compared with intrahepatic-arterial technetium-99m macroaggregated albumin scan in hepatocellular carcinoma.

Leung TW, Lau WY, Ho SK, Chan M, Leung NW, Lin J, Metreweli C, Johnson PJ, Li AK. Leung TW, et al. Among authors: johnson pj. Cancer Chemother Pharmacol. 1994;33 Suppl:S33-6. doi: 10.1007/BF00686665. Cancer Chemother Pharmacol. 1994. PMID: 8137482

5

Measuring lung shunting in hepatocellular carcinoma with intrahepatic-arterial technetium-99m macroaggregated albumin.

Leung WT, Lau WY, Ho SK, Chan M, Leung NW, Lin J, Metreweli C, Johnson PJ, Li AK. Leung WT, et al. Among authors: johnson pj. J Nucl Med. 1994 Jan;35(1):70-3. J Nucl Med. 1994. PMID: 8271063 Free article.

6

Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours.

Ho S, Lau WY, Leung TW, Chan M, Ngar YK, Johnson PJ, Li AK. Ho S, et al. Among authors: johnson pj. Eur J Nucl Med. 1996 Aug;23(8):947-52. doi: 10.1007/BF01084369. Eur J Nucl Med. 1996. PMID: 8753684

7

Serum levels of CYFRA 21-1 in nasopharyngeal carcinoma and its possible role in monitoring of therapy.

Ho S, Leung WT, Yuen J, Johnson PJ. Ho S, et al. Among authors: johnson pj. Eur J Cancer B Oral Oncol. 1996 Nov;32B(6):377-80. doi: 10.1016/s0964-1955(96)00017-6. Eur J Cancer B Oral Oncol. 1996. PMID: 9039220

8

Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer.

Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK. Ho S, et al. Among authors: johnson pj. Eur J Nucl Med. 1997 Mar;24(3):293-8. doi: 10.1007/BF01728766. Eur J Nucl Med. 1997. PMID: 9143467

9

Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes.

Yeo W, Chan KK, Mukwaya G, Ross M, Leung WT, Ho S, Chan AT, Johnson PJ. Yeo W, et al. Among authors: johnson pj. Cancer Chemother Pharmacol. 1999;44(2):124-30. doi: 10.1007/s002800050956. Cancer Chemother Pharmacol. 1999. PMID: 10412946 Clinical Trial.

10

What determines survival duration in hepatocellular carcinoma treated with intraarterial Yttrium-90 microspheres?

Lau WY, Ho S, Leung WT, Chan M, Lee WY, Johnson PJ. Lau WY, et al. Among authors: johnson pj. Hepatogastroenterology. 2001 Mar-Apr;48(38):338-40. Hepatogastroenterology. 2001. PMID: 11379304

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

958 results

Search Page

Filters